AstraZeneca’s Soliris® Is Approved in Malaysia for Treatment of Rare Neurological Autoimmune Diseases and Severe Blood Disorders
Soliris®: Targeting of Complement System to Improve Clinical Outcomes in Rare Disease AstraZeneca, a global, science-led biopharmaceutical company, has made available its treatment, Soliris®, in Malaysia as part of its ongoing commitment to support patients
Continue reading
